Now Approved: U.S. FDA approves product to reduce the incidence of catheter-related bloodstream infections (CRBSIs) under special pathway for patients receiving hemodialysis.
CorMedix Inc. Rings the NYSE Closing Bell on June 10, 2019
You are now leaving cormedix.com
Would you like to proceed?
